Viking Therapeutics Inc. (VKTX)

Viking Therapeutics (VKTX -1.12%) has intrigued investors over the past year and a half because it's involved in a potential David and Goliath story. Today, pharma giants Eli Lilly and Novo Nordisk do...

VKTX stock slumps after mixed obesity pill study results raise safety concerns and highlight fierce market competition.

Viking Therapeutics, Inc. (VKTX) reached $27.05 at the closing of the latest trading day, reflecting a -1.92% change compared to its last close.

Eric Volkman has no position in any of the stocks mentioned. The Motley Fool recommends Viking Therapeutics.

NVO and VKTX face setbacks and rising competition as they battle for ground in the GLP-1 obesity market.

This year has offered no shortage of market-moving headlines shaping investor sentiment. Mixed job reports, new tariffs fueling turbulence in U.S. trade policy, and ongoing uncertainty around Federal ...

Viking Therapeutics (VKTX -0.69%) delivered one of the most anticipated obesity readouts of the year -- and Wall Street promptly panicked. Shares plummeted 40% after the company released Phase 2 resul...

Viking Therapeutics (VKTX 1.32%) and Regeneron Pharmaceuticals (REGN -1.45%) have faced challenges this year that have sunk their stock prices. The former is down by 37% this year, while the latter ha...

Viking's oral VK2735 efficacy was strong, but tolerability issues and high discontinuation rates cloud its competitive edge in the obesity drug market. The market's perception of Viking shifted after ...

Shares in Viking Therapeutics (VKTX 1.13%) crashed by 35.9% in the week to Friday morning. The decline comes in a week when the company released its top-line results from its phase 2 trial of its lead...